154 related articles for article (PubMed ID: 17172428)
1. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer.
Mistry SJ; Atweh GF
Mol Cancer Ther; 2006 Dec; 5(12):3248-57. PubMed ID: 17172428
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer.
Miceli C; Tejada A; Castaneda A; Mistry SJ
Cancer Gene Ther; 2013 May; 20(5):298-307. PubMed ID: 23618950
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure.
Mistry SJ; Bank A; Atweh GF
Mol Cancer Res; 2007 Aug; 5(8):773-82. PubMed ID: 17670914
[TBL] [Abstract][Full Text] [Related]
4. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.
Hahn SM; Liebmann JE; Cook J; Fisher J; Goldspiel B; Venzon D; Mitchell JB; Kaufman D
Cancer; 1993 Nov; 72(9):2705-11. PubMed ID: 8104682
[TBL] [Abstract][Full Text] [Related]
5. Targeting stathmin in prostate cancer.
Mistry SJ; Bank A; Atweh GF
Mol Cancer Ther; 2005 Dec; 4(12):1821-9. PubMed ID: 16373697
[TBL] [Abstract][Full Text] [Related]
6. Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle.
Iancu C; Mistry SJ; Arkin S; Atweh GF
Cancer Res; 2000 Jul; 60(13):3537-41. PubMed ID: 10910066
[TBL] [Abstract][Full Text] [Related]
7. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
Vadgama JV; Wu Y; Shen D; Hsia S; Block J
Anticancer Res; 2000; 20(3A):1391-414. PubMed ID: 10928049
[TBL] [Abstract][Full Text] [Related]
8. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
Nomura T; Yamasaki M; Nomura Y; Mimata H
Oncol Rep; 2005 Oct; 14(4):993-7. PubMed ID: 16142363
[TBL] [Abstract][Full Text] [Related]
9. Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice.
Lin X; Yu T; Zhang L; Chen S; Chen X; Liao Y; Long D; Shen F
Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):611-620. PubMed ID: 27289016
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors.
Dong YB; Yang HL; Elliott MJ; McMasters KM
Cancer Res; 2002 Mar; 62(6):1776-83. PubMed ID: 11912154
[TBL] [Abstract][Full Text] [Related]
11. Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.
Lin X; Liao Y; Xie J; Liu S; Su L; Zou H
Cancer Biother Radiopharm; 2014 Nov; 29(9):376-86. PubMed ID: 25379611
[TBL] [Abstract][Full Text] [Related]
12. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines.
Wigington DP; Urben CM; Strugnell SA; Knutson JC
Anticancer Res; 2004; 24(5A):2905-12. PubMed ID: 15517895
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
14. Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.
Balasubramani M; Nakao C; Uechi GT; Cardamone J; Kamath K; Leslie KL; Balachandran R; Wilson L; Day BW; Jordan MA
Mutat Res; 2011 Jun; 722(2):154-64. PubMed ID: 20816848
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
Papadopoulou MV; Ji M; Bloomer WD
Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
[TBL] [Abstract][Full Text] [Related]
17. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle.
Mistry SJ; Benham CJ; Atweh GF
Antisense Nucleic Acid Drug Dev; 2001 Feb; 11(1):41-9. PubMed ID: 11258620
[TBL] [Abstract][Full Text] [Related]
18. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine.
Dorie MJ; Brown JM
Cancer Chemother Pharmacol; 1997; 39(4):361-6. PubMed ID: 9025778
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.
Gurnani M; Lipari P; Dell J; Shi B; Nielsen LL
Cancer Chemother Pharmacol; 1999; 44(2):143-51. PubMed ID: 10412949
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cyclin A kinase activity in E2F-1 chemogene therapy of colon cancer.
Elliott MJ; Baker JD; Dong YB; Yang HL; Gleason JF; McMasters KM
Tumour Biol; 2002; 23(6):324-36. PubMed ID: 12677090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
